amphetamine and dextroamphetamine

This page shows the latest amphetamine and dextroamphetamine news and features for those working in and with pharma, biotech and healthcare.

Shire weathers generic Adderall XR challenge

attention deficit-hyperactivity disorder (ADHD) drug Adderall XR (amphetamine and dextroamphetamine). ... as well as Intuniv (guanfacine) - another ADHD drug - and treatment for hereditary angioedema Firazyr (icatibant).

Latest news

Shire's Q3 net profit doubles

Net profit for Shire recovers from payment to Acceleron and impairment charges relating to the divestment of Daytrana. ... Products that performed particularly well in the quarter included ADHD treatments Vyvanse (lisdexamfetamine) and Adderall XR
Shire ADHD scholarship programme

Applicants' work experience, volunteer/extracurricular activities, and academic transcripts will also be taken into account. ... use as adjunctive therapy to stimulants; the extended-release drug Vyvanse (lisdexamfetamine dimesylate), which was approved
New use cleared for Shire ADHD drug

The FDA has approved Shire's ADHD drug Intuniv for the new indication of adjunctive therapy to stimulants in children and adolescents aged six to 17. ... The company's ADHD portfolio also includes the extended-release drug VyVanse (lisdexamfetamine

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....